Wednesday, November 29, 2023

New COVID Variant Spreading in US, Experts Explain Risks
Compared to Eris, BA.2.86 has a significantly lower growth efficiency, meaning that it is less capable of replicating itself in the human bodies.

The new BA.2.86 variant, unofficially known as Pirola is taking hold in the United States.

Between Oct. 28 to Nov. 25, its prevalence increased from 1 to around 9 percent in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).

The World Health Organization designated Pirola as a variant of interest on Nov. 21, yet it also found the public health risk posed by BA.2.86 to be “low at the global level (pdf).”
In an update published on Nov. 27, the CDC agreed with the WHO’s assessment “that the public health risk posed by this variant is low compared with other circulating variants, based on available limited evidence.”

Current Research Suggests Low Risk of Disease

Pirola is derived from BA.2, an earlier Omicron variant.
Other variants derived from BA.2 include XBB.1.5 which became the dominant strain in early 2023.

The current dominant variant is H.V.1, and it is derived from the variant EG.5, unofficially known as Eris, a previously dominant variant in the United States.

“At this time, BA.2.86 does not appear to be driving increases in infections or hospitalizations in the United States,” the CDC wrote.

Research outside of the United States similarly suggests that Pirola should not be more severe than current variants.

Researcher Yunlong Cao, who holds a doctorate in physical biochemistry from Harvard found that Pirola “exhibits lower cell infectivity” compared to XBB.1.5 and Eris.

A preprint study from Japan found that while Pirola may be more transmissible than Eris a previous dominant variant, it is less likely to cause disease.

Compared to Eris, Pirola has a significantly lower growth efficiency, meaning that it is less capable of replicating itself in the host, the authors wrote.

“This is not the second coming of omicron. If it were, it is safe to say we would know by now,” Bill Hanage, associate director and professor of epidemiology at Harvard wrote on X on Sep. 1 ,when the variant's prevalence was significantly lower.

Prior Infections Gives Immunity Against the New Variant

Compared to BA.2, its ancestral subvariant, Pirola has more than 30 mutations in its spike protein. The virus uses the spike protein to infect human cells.

The substantial number of mutations initially raised concerns among virologists, who feared this variant might partially evade earlier immunity from previous exposure, whether from natural infection or prior vaccination.

However, evidence is still lacking to predict if there will be more immune evasions as well as the severity of future Pirola cases.

Mr. Cao’s own research in mice who have been vaccinated or infected with XBB vaccines showed that the antibodies generated “cannot well recognize and neutralize BA.2.86,” he wrote in a thread posted on the social media platform, X.

However, Pirola had a low cell infectivity, which can affect the variant's transmission, he added.

In discussion of Mr. Cao’s findings, Mr. Hanage agreed that immune evasion is not a definite indication of more severe infection and transmission.

“Any hopeful virus has to have some immune evasion, because almost everyone has immunity,” he wrote.

The most recent research on Pirola's immune evasion abilities comes from a series of reports conducted by researchers at Columbia University.

The first study, published in Nature, tested Pirola, XBB1.5, and Eris spike proteins against antibodies produced from a breakthrough XBB infection.

These antibodies conferred robust neutralizing activity against Pirola. The authors also noted that Pirola's ability to evade immunity was no better than that of XBB1.5 and EG.5.

The same group of researchers then tested antibodies produced from the new XBB1.5 COVID vaccine against several variants, including XBB1.5, Eris, and JN.1, a derivative of Pirola. The findings were published in a preprint.

The authors found that, compared to all variants investigated, JN.1 was the most immune evasive against antibodies produced from the vaccine.

HV.1: The Current Dominant Variant

The current dominant subvariant is HV.1, a new variant derived from Eris. Eris is currently the most dominant globally and HV.1 succeeded Eris as the dominating variant in the U.S. on Oct. 28.

Like Pirola, the WHO has classified HV.1 as a variant with low public health risk. The variant accounted for about 31.5 percent of all cases in the United States as of Nov. 25.


Is It Possible that COVID-19 Boosters Trigger a Cancer Relapse?

COVID-19 boosters are used to activate the immune response by synthesizing antibodies against foreign pathogens, however, some adverse events have been associated with these boosters. In the aggregate via published case series alone, over two hundred cases of cancer or cancer relapse have been reported yesterday by TrialSite. Yet none of these cases can prove causation (the studies aren’t designed for that), and the incidence remain rare given over 230 million people are considered fully vaccinated in America alone. Regardless, several cases of cancer relapse have been reported after the administration of COVID-19 boosters, according to Angus Dalgleish, a professor of oncology at St.George’s University of London. During an interview, he raised his concerns about the COVID-19 boosters’ long-term consequences, perturbation of the immune system, and the development or relapse of aggressive cancers. TrialSite investigates the reports of cancer related to COVID-19 vaccination.

Dr. John Campbell, a retired British nurse and healthcare educator, interviewed Professor Dalgleish to discuss his insights into boosters, immunity, and cancer risk. The focus of Dalgleish’s extensive research is immunotherapies and cancer vaccines. In this interview, he described his observations on patients suffering from melanoma.

Melanoma is a type of skin cancer that forms in the skin cells called melanocytes. These cells produce melanin which gives color to the skin. The exact cause of melanomas is still unclear, but it is widely accepted that exposure to ultraviolet radiation from sunlight is the reason for the rapid rise in melanoma cases worldwide. It is easy to treat it if it gets detected at an early stage.

Dalgleish’s observations on melanoma patients

Dalgleish observed cancer patients’ response to immunotherapies (use of the body’s own defense system to fight against diseases) and realized that vitamin D deficiency is associated with melanoma. Moreover, he added that improving the body’s vitamin D status can enhance immunotherapy outcomes.

Several studies support Dalgleish’s claim that vitamin D deficiency is associated with melanoma. A retrospective cohort study in 2022 found that vitamin D deficiency is responsible for worsening the overall survival of melanoma patients. Yet observational studies such as the latter cannot necessarily establish causation.

Additionally, an experimental study suggested that vitamin D deficiency is associated with thicker melanoma tumors, which can cause poor prognosis at the time of diagnosis.

Dalgleish also noted that melanoma patients often return with a cancer relapse even after 20 years. By observing their medical history, he noticed that these patients had experienced stress like divorce, bereavement, or bankruptcy, which caused immune suppression for a significant period. He also realized that there was another factor that increased the relapse rate – receiving a COVID-19 booster shot.

According to Prof. Dalgleish, these boosters are meant to enhance the immune response, but the relapse of cancer raises questions about their effect on immune response.

The mechanism behind the increased relapse

Dalgleish suggests the vaccines mostly deal with antibodies while laying more emphasis on the importance of innate immune response by activating T-cells. These cells effectively remove cancer cells and viral-infected cells. Also, these act during the time when the effective adaptive immune response (antibody production) is in the process of developing. T-cell activity reduces with age, particularly after age 55, which increases the incidence rate of cancer in elderly people.

The boosters do not cause the body to make IgG1 and IgG3, which are neutralizing antibodies, instead, they switch to IgG4 antibodies which are less effective in combating infection or disease. These IgG4 antibodies suppress the T-cell response which causes a suppression in the fast-acting innate immune response. This, according to the hypothesis, increases the chance of cancer relapse in people after getting COVID-19 boosters. But this would need to be fully investigated for any affirmative declarations, would it not?

Immune system perturbation linked to cancer

Dalgleish mentioned that there are many unnecessary antibodies formed inside the body following COVID-19 boosters. He called this “antibody-dependent enhancement.”

Antibody-dependent enhancement refers to a situation in which antibodies emerge during an immune response but do not prevent an infection. Instead, these antibodies actually help the virus penetrate the cells. Thus, Dalgleish claimed that boosters do not provide protection instead, they perturb the immune system and cause more aggressive forms of cancer. He gave an example case of lymphoma diagnosis in one of his colleagues after vaccination.

The London-based oncologist implies of the possibility of emerging cancers such as B-cell leukemia and renal cancers in the near future due to immune system perturbation induced by vaccines. Again this would need to be formally studied, as the observations of one physician or even a handful doesn’t equate to evidence.

Potential impacts of mRNA vaccines on the immune system

In the interview, Dalgleish also talked about mRNA vaccines. He expressed his frustration over the use of the SV40 promoter in mRNA vaccines and explained that it is an oncogenic promoter used for developing cancer in mice.

The oncologist suggests questions about the composition and potential risks of mRNA vaccines. He also extended his concern to the integration of DNA. TrialSite previously published an article analyzing these claims of DNA contamination in Pfizer and Moderna mRNA-based COVID-19 vaccines. While numerous activists critical of the COVID-19 vaccines have pounced on “plasmidgate,” TrialSite has been clear that some of the studies are questionable—such as the German study where most of the vaccine vials were opened upon arrival at the third-party lab doing the testing.

Given the testimony of Professor Philip Buckhaults in front of the South Carolina Senate on the matter TrialSite has suggested formal, government, and industry investigations.

TrialSite’s founder Daniel O’Connor, an expert in Food and Drug Administration (FDA) regulated clinical research process and technologies, was in touch with leadership at the regulatory agency who committed to passing along the information. But the TrialSite publisher told this writer, “The regulators don’t seem too concerned at all about the reports of DNA snippets in the vaccine samples.”

What about the Spike Protein?

There are claims that the spike protein, which was held responsible for vaccine injuries, remained at the injection site and did not integrate. The formal narrative has it that the spike protein flushes from the lymphatic system within a week or so but enough published material has emerged to refute that oversimplified claim.

Dalgleish challenges the premise powering claims for a lack of spike integration.

To examine these claims, autopsies need to be done but Dalgleish points to the difficulty of doing autopsies on patients who had died after vaccination. He said that it had been overruled despite obtaining relatives’ consent for post-mortems. This caused a lack of transparency.

Censorship and media influence also represent formidable issues because the government discouraged criticism of vaccines argues the oncologist. This hinders open discussions about vaccine safety and effectiveness.




No comments: